Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

78 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Characterization of murine CEACAM1 in vivo reveals low expression on CD8+ T cells and no tumor growth modulating activity by anti-CEACAM1 mAb CC1.
McLeod RL, Angagaw MH, Baral TN, Liu L, Moniz RJ, Laskey J, Hsieh S, Lee M, Han JH, Issafras H, Javaid S, Loboda A, Sadekova S, O'Connor JA, Tse A, Punnonen J. McLeod RL, et al. Among authors: punnonen j. Oncotarget. 2018 Oct 2;9(77):34459-34470. doi: 10.18632/oncotarget.26108. eCollection 2018 Oct 2. Oncotarget. 2018. PMID: 30349641 Free PMC article.
Antitumor efficacy of combined CTLA4/PD-1 blockade without intestinal inflammation is achieved by elimination of FcγR interactions.
Bauché D, Mauze S, Kochel C, Grein J, Sawant A, Zybina Y, Blumenschein W, Yang P, Annamalai L, Yearley JH, Punnonen J, Bowman EP, Chackerian A, Laface D. Bauché D, et al. Among authors: punnonen j. J Immunother Cancer. 2020 Oct;8(2):e001584. doi: 10.1136/jitc-2020-001584. J Immunother Cancer. 2020. PMID: 33127658 Free PMC article.
TransCon IL-2 β/γ: a novel long-acting prodrug with sustained release of an IL-2Rβ/γ-selective IL-2 variant with improved pharmacokinetics and potent activation of cytotoxic immune cells for the treatment of cancer.
Rosen DB, Kvarnhammar AM, Laufer B, Knappe T, Karlsson JJ, Hong E, Lee YC, Thakar D, Zúñiga LA, Bang K, Sabharwal SS, Uppal K, Olling JD, Kjaergaard K, Kurpiers T, Schnabel M, Reich D, Glock P, Zettler J, Krusch M, Bernhard A, Heinig S, Konjik V, Wegge T, Hehn Y, Killian S, Viet L, Runz J, Faltinger F, Tabrizi M, Abel KL, Breinholt VM, Singel SM, Sprogøe K, Punnonen J. Rosen DB, et al. Among authors: punnonen j. J Immunother Cancer. 2022 Jul;10(7):e004991. doi: 10.1136/jitc-2022-004991. J Immunother Cancer. 2022. PMID: 35817480 Free PMC article. Clinical Trial.
78 results